Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 247 publications
Prognostic factors for early mortality following allogeneic hematopoietic cell transplantation in hematologic malignancies.
Journal: Transplantation and cellular therapy
Published: May 26, 2026
Prognostic Factors for Early Mortality Following Allogeneic Hematopoietic Cell Transplantation in Hematologic Malignancies.
Journal: Transplantation and cellular therapy
Published: May 26, 2026
Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 14, 2026
Review of the first on-body injector (OBI) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma.
Journal: Expert opinion on drug delivery
Published: April 13, 2026
Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 10, 2026
Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.
Journal: American journal of hematology
Published: March 31, 2026
Adopting a Standard of Care for Systemic Sclerosis: The Mayo Clinic Experience.
Journal: Arthritis care & research
Published: February 24, 2026
Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia.
Journal: Expert review of hematology
Published: February 10, 2026
Prospective patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment attributes and factors affecting patient shared decision-making in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in the United States (US).
Journal: Expert review of hematology
Published: January 13, 2026
Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasone.
Journal: Haematologica
Published: December 21, 2025
A phase II study of daratumumab and ibrutinib for relapsed/refractory chronic lymphocytic leukemia.
Journal: Blood cancer journal
Published: December 12, 2025
Last Updated: 09/26/2026